Andrea Kazumi Shimada

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC

Franciele Hinterholz Knebel, Fabiana Bettoni, Andrea Kazumi Shimada et al. · Lung Cancer · 2017 · 73 citations

Egfr Driver Mutations, Sclerostin, Bone Morphogenic Protein +7

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni et al. · npj Precision Oncology · 2021 · 41 citations · Full text

Evaluation of organ doses in CT examinations with an infant anthropomorphic phantom

Keisuke Fujii, Keiichi Akahane, Osamu Miyazaki et al. · Radiation Protection Dosimetry · 2011 · 18 citations

Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series

Maurício Fernando Silva Almeida Ribeiro, Joao V. Alessi, Leandro Jonata de Carvalho Oliveira et al. · Lung Cancer · 2019 · 18 citations · Full text